i2O Therapeutics is focused on developing innovative therapies for cardio-renal-metabolic diseases through its proprietary "4D" GLP-1 combinations. The company has a robust pipeline that includes two long-acting GLP-1 receptor agonists, two long-acting amylin agonists, as well as long-acting PYY and glucagon. These technologies aim to provide differentiated treatment options that are designed to improve patient outcomes in managing complex metabolic conditions.

The company's approach emphasizes a data-rich and de-risked strategy, ensuring that their pipeline assets are backed by documented freedom to operate (FTO) and intellectual property (IP). This commitment to scientific rigor and innovation positions i2O Therapeutics as a leader in the development of next-generation therapies that target multiple pathways involved in metabolic diseases, potentially offering new hope for patients suffering from these chronic conditions.

United States

2o Therapeutics is Boston-based company developing next generation biologic therapies

i2O Therapeutics

Company Details